Maple syrup urine disease (MSUD) results from branched-chain alpha-keto acid dehydrogenase (BCKDH) complex deficiency. The toxic metabolites in MSUD cause cerebral edema and neurological deterioration primarily by:
- A Elevated leucine allosterically inhibiting glutamate dehydrogenase, depleting alpha-ketoglutarate for TCA cycle
- B Branched-chain keto acids (particularly alpha-ketoisocaproate from leucine) inhibit pyruvate dehydrogenase, cause mitochondrial dysfunction, and deplete myelination precursors ✓
- C Excess isoleucine competitively inhibits GABA transaminase, causing neurotransmitter imbalance
- D Accumulation of valine keto acid depletes alpha-ketoglutarate, blocking transamination reactions and reducing neurotransmitter synthesis
Explanation
Accumulated branched-chain keto acids (BCKAs), especially alpha-ketoisocaproate (from leucine), are the primary neurotoxins in MSUD. They inhibit pyruvate dehydrogenase (impair aerobic glucose metabolism, worsening energy deficit in brain), generate reactive oxygen species causing mitochondrial dysfunction, and impair transport of large neutral amino acids across the blood-brain barrier (reducing tryptophan, tyrosine, phenylalanine for neurotransmitter synthesis). Leucine itself disrupts mTOR regulation and myelin synthesis. Cerebral edema results from osmotic and metabolic effects. The maple syrup odor is from sotolone (a by-product of BCKA metabolism).
Reference: Harper's Illustrated Biochemistry, 32nd ed.
High-yield for: NEET PGINI-CETNExTFMGEUSMLEPLABMRCP
Written and medically reviewed by the StethoPrep medical team.